|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-8-28
|
|
pubmed:abstractText |
Since cefuroxime mainly is excreted by renal filtration, dosing is currently based on serum creatinine (Scr) or creatinine clearance (CLcr). However, it has been suggested that cystatin C (CysC) is superior to Scr as a marker of renal function. The aim of this prospective study was to develop a population model that describes the pharmacokinetics of cefuroxime and to investigate the usefulness of CysC as a covariate of the model parameters.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-11468939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-11750834,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-12148093,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-1244564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-1394976,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-1475176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-15025426,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-15052582,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-15508527,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-15837759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-2328296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-2363674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-479064,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-590309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-6861853,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-7247369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-7340882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-7785962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-8138894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-8869663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-9127103,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-949172,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16934045-9839090
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
297-303
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16934045-Anti-Bacterial Agents,
pubmed-meshheading:16934045-Biological Markers,
pubmed-meshheading:16934045-Cefuroxime,
pubmed-meshheading:16934045-Cystatin C,
pubmed-meshheading:16934045-Cystatins,
pubmed-meshheading:16934045-Dose-Response Relationship, Drug,
pubmed-meshheading:16934045-Female,
pubmed-meshheading:16934045-Humans,
pubmed-meshheading:16934045-Kidney,
pubmed-meshheading:16934045-Kidney Function Tests,
pubmed-meshheading:16934045-Male,
pubmed-meshheading:16934045-Middle Aged
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.
|
|
pubmed:affiliation |
Division of Pharmokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. anders.viberg@farmbio.uu.se
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
